Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.

Linzhang LiChengwu HanXueying YuJun ShenYongtong Cao

Published in: Journal of healthcare engineering (2022)

The combination of AZD4573 and 10058-F4 has a synergistic anti-araC-resistant AML activity, providing a solid database for the aforementioned scientific hypothesis.

Keyphrases

acute myeloid leukemia
cancer therapy
allogeneic hematopoietic stem cell transplantation
cell cycle
emergency department
drug delivery
adverse drug
cell proliferation